Skip to content

Released Nov 14, 2022, after the close

10-Q filed Nov 14, 2022, 45 days after period end · 0000950170-22-024971

Q3 2022 · 10-Q
Revenue$1.08M+52.8% vs Q3 2021+20.8% vs Q2 2022
Net Income-$11.70MN/M vs Q3 2021N/M vs Q2 2022
EPS Diluted-$0.33N/M vs Q3 2021N/M vs Q2 2022
Operating Income-$11,834,000N/M
Operating Cash Flowderived-$957,000N/M
Margins · derived
Operating margin-1093.7%+2087.6 pt vs Q3 2021
Net margin-1081.3%+2096.6 pt vs Q3 2021

What the release said

The release

Same quarter

MetricQ3 2022Q3 2021Q3 2020Q3 2019
Revenue$1.08M$708.00K$38.00K$172.00K
Net Income-$11.70M-$22.50M-$18.90M-$17.70M
EPS Diluted-$0.33-$0.70-$0.86-$0.95

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Spero Therapeutics, Inc. · CIK 1701108 · Engraved from SEC EDGAR